An Optimised GA Interventional Trial (Opti-GAIN) to Test if Treatment With CTx001 is Safe and Works for People With Geographic Atrophy (GA)

Exclusion Criteria

• •Macular atrophy or retinal disease not attributable to AMD
• •Evidence of current or prior choroidal neovascularization (wet AMD)
• •Prior intraocular, macular, or retinal surgery or laser treatment that may confound assessments
• •Prior AMD-directed or intravitreal therapy in the study eye, except permitted supplements
• •Prior exposure to complement inhibitor therapies
• •Ocular conditions, infections, inflammation, or media opacities that interfere with safety or retinal imaging
• •Uncontrolled glaucoma, diabetic retinopathy, or clinically significant refractive error
• •Aphakia or compromised posterior capsule, except as permitted by protocol
• •Systemic medical or psychiatric conditions that may increase risk or limit compliance
• •Recent participation in another interventional clinical study or exposure to investigational therapies
• •Any condition that, in the investigator's judgment, poses unacceptable risk or precludes safe participation